Effect of human pancreastatin peptide (hP-16) on oral glucose tolerance in man

Le résumé fourni par la source

The gastrointestinal peptide, pancreastatin, has been shown to inhibit insulin release and exocrine pancreatic secretion in the rat. Human pancreastatin-like peptides first isolated from a carcinoid tumor, are expressed in human islets of Langerhans. To investigate the influence of human pancreastatin-16 (hP-16) on oral glucose tolerance (OGTT) in non-diabetic humans, we synthesized the C-terminally amidated human pancreastatin peptide. Healthy male volunteers (n = 6) received in a double-blind placebo-controlled study a 75 g standard OGTT during the i.v. infusion of hP-16 (10 pmol/kg/min) or saline over a time period of 3 h. Peak glucose levels (mg/dl) declined from 151.4 +/- 10.3 (control) to 122.5 +/- 9.7 (hP-16) (mean +/- SEM), peak insulin levels (microU/ml) from 46.3 +/- 2.9 (hP-16) to 32.2 +/- 4.0 (control) and peak C-peptide levels (pmol/ml) from 1.9 +/- 0.1 (hP-16) to 1.2 +/- 0.1 (control). Integrated incremental glucose, insulin and C-peptide responses were reduced by 47% (p < 0.001), 23% (p < 0.05) and 15% (p < 0.05), respectively. In conclusion, these findings indicate that hP-16 attenuates the elevation of blood glucose and insulin levels after an oral glucose load in non-diabetic humans.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.